Colon Cancer, Version 1.2017, NCCN Clinical Practice Guidelines in Oncology

Restricted access

This portion of the NCCN Guidelines for Colon Cancer focuses on the use of systemic therapy in metastatic disease. Considerations for treatment selection among 32 different monotherapies and combination regimens in up to 7 lines of therapy have included treatment history, extent of disease, goals of treatment, the efficacy and toxicity profiles of the regimens, KRAS/NRAS mutational status, and patient comorbidities and preferences. Location of the primary tumor, the BRAF mutation status, and tumor microsatellite stability should also be considered in treatment decisions.

  • 1.

    Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin 2016;66:730.

  • 2.

    Cheng L, Eng C, Nieman LZ. Trends in colorectal cancer incidence by anatomic site and disease stage in the United States from 1976 to 2005. Am J Clin Oncol 2011;34:573580.

    • Search Google Scholar
    • Export Citation
  • 3.

    Henley SJ, Singh SD, King J. Invasive cancer incidence and survival—United States, 2011. MMWR Morb Mortal Wkly Rep 2015;64:237242.

  • 4.

    Siegel R, Ward E, Brawley O, Jemal A. Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin 2011;61:212236.

    • Search Google Scholar
    • Export Citation
  • 5.

    Bailey CE, Hu CY, You YN. Increasing disparities in the age-related incidences of colon and rectal cancers in the United States, 1975-2010. JAMA Surg 2014:16.

    • Search Google Scholar
    • Export Citation
  • 6.

    Amin MB, Greene FL, Edge S, eds. AJCC Cancer Staging Manual, 8th ed. New York: Springer; 2016.

  • 7.

    Amado RG, Wolf M, Peeters M. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 2008;26:16261634.

    • Search Google Scholar
    • Export Citation
  • 8.

    Andre T, Louvet C, Maindrault-Goebel F. CPT-11 (irinotecan) addition to bimonthly, high-dose leucovorin and bolus and continuous-infusion 5-fluorouracil (FOLFIRI) for pretreated metastatic colorectal cancer. GERCOR. Eur J Cancer 1999;35:13431347.

    • Search Google Scholar
    • Export Citation
  • 9.

    Bartlett DL, Berlin J, Lauwers GY. Chemotherapy and regional therapy of hepatic colorectal metastases: expert consensus statement. Ann Surg Oncol 2006;13:12841292.

    • Search Google Scholar
    • Export Citation
  • 10.

    Buroker TR, O'Connell MJ, Wieand HS. Randomized comparison of two schedules of fluorouracil and leucovorin in the treatment of advanced colorectal cancer. J Clin Oncol 1994;12:1420.

    • Search Google Scholar
    • Export Citation
  • 11.

    Cassidy J, Clarke S, Diaz-Rubio E. Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer. J Clin Oncol 2008;26:20062012.

    • Search Google Scholar
    • Export Citation
  • 12.

    Cheeseman SL, Joel SP, Chester JD. A ‘modified de Gramont’ regimen of fluorouracil, alone and with oxaliplatin, for advanced colorectal cancer. Br J Cancer 2002;87:393399.

    • Search Google Scholar
    • Export Citation
  • 13.

    Colucci G, Gebbia V, Paoletti G. Phase III randomized trial of FOLFIRI versus FOLFOX4 in the treatment of advanced colorectal cancer: a multicenter study of the Gruppo Oncologico Dell'Italia Meridionale. J Clin Oncol 2005;23:48664875.

    • Search Google Scholar
    • Export Citation
  • 14.

    Cunningham D, Humblet Y, Siena S. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004;351:337345.

    • Search Google Scholar
    • Export Citation
  • 15.

    Cunningham D, Pyrhonen S, James RD. Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet 1998;352:14131418.

    • Search Google Scholar
    • Export Citation
  • 16.

    de Gramont A, Bosset JF, Milan C. Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: a French intergroup study. J Clin Oncol 1997;15:808815.

    • Search Google Scholar
    • Export Citation
  • 17.

    de Gramont A, Figer A, Seymour M. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000;18:29382947.

    • Search Google Scholar
    • Export Citation
  • 18.

    Delaunoit T, Goldberg RM, Sargent DJ. Mortality associated with daily bolus 5-fluorouracil/leucovorin administered in combination with either irinotecan or oxaliplatin: results from Intergroup trial N9741. Cancer 2004;101:21702176.

    • Search Google Scholar
    • Export Citation
  • 19.

    Douillard JY, Cunningham D, Roth AD. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 2000;355:10411047.

    • Search Google Scholar
    • Export Citation
  • 20.

    Douillard JY, Siena S, Cassidy J. Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. J Clin Oncol 2010;28:46974705.

    • Search Google Scholar
    • Export Citation
  • 21.

    Falcone A, Ricci S, Brunetti I. Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest. J Clin Oncol 2007;25:16701676.

    • Search Google Scholar
    • Export Citation
  • 22.

    Fuchs CS, Moore MR, Harker G. Phase III comparison of two irinotecan dosing regimens in second-line therapy of metastatic colorectal cancer. J Clin Oncol 2003;21:807814.

    • Search Google Scholar
    • Export Citation
  • 23.

    Giantonio BJ, Catalano PJ, Meropol NJ. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol 2007;25:15391544.

    • Search Google Scholar
    • Export Citation
  • 24.

    Goldberg RM. Therapy for metastatic colorectal cancer. Oncologist 2006;11:981987.

  • 25.

    Goldberg RM, Rothenberg ML, Van Cutsem E. The continuum of care: a paradigm for the management of metastatic colorectal cancer. Oncologist 2007;12:3850.

    • Search Google Scholar
    • Export Citation
  • 26.

    Goldberg RM, Sargent DJ, Morton RF. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 2004;22:2330.

    • Search Google Scholar
    • Export Citation
  • 27.

    Grothey A, Van Cutsem E, Sobrero A. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet 2013;381:303312.

    • Search Google Scholar
    • Export Citation
  • 28.

    Haller DG, Rothenberg ML, Wong AO. Oxaliplatin plus irinotecan compared with irinotecan alone as second-line treatment after single-agent fluoropyrimidine therapy for metastatic colorectal carcinoma. J Clin Oncol 2008;26:45444550.

    • Search Google Scholar
    • Export Citation
  • 29.

    Hurwitz HI, Fehrenbacher L, Hainsworth JD. Bevacizumab in combination with fluorouracil and leucovorin: an active regimen for first-line metastatic colorectal cancer. J Clin Oncol 2005;23:35023508.

    • Search Google Scholar
    • Export Citation
  • 30.

    Jager E, Heike M, Bernhard H. Weekly high-dose leucovorin versus low-dose leucovorin combined with fluorouracil in advanced colorectal cancer: results of a randomized multicenter trial. Study Group for Palliative Treatment of Metastatic Colorectal Cancer Study Protocol 1. J Clin Oncol 1996;14:22742279.

    • Search Google Scholar
    • Export Citation
  • 31.

    Kabbinavar FF, Hambleton J, Mass RD. Combined analysis of efficacy: the addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer. J Clin Oncol 2005;23:37063712.

    • Search Google Scholar
    • Export Citation
  • 32.

    Kelly H, Goldberg RM. Systemic therapy for metastatic colorectal cancer: current options, current evidence. J Clin Oncol 2005;23:45534560.

    • Search Google Scholar
    • Export Citation
  • 33.

    Kohne CH, Hofheinz R, Mineur L. First-line panitumumab plus irinotecan/5-fluorouracil/leucovorin treatment in patients with metastatic colorectal cancer. J Cancer Res Clin Oncol 2012;138:6572.

    • Search Google Scholar
    • Export Citation
  • 34.

    Maindrault-Goebel F, Louvet C, Andre T. Oxaliplatin added to the simplified bimonthly leucovorin and 5-fluorouracil regimen as second-line therapy for metastatic colorectal cancer (FOLFOX6). GERCOR. Eur J Cancer 1999;35:13381342.

    • Search Google Scholar
    • Export Citation
  • 35.

    Mayer RJ, Van Cutsem E, Falcone A. Randomized trial of TAS-102 for refractory metastatic colorectal cancer. N Engl J Med 2015;372:19091919.

  • 36.

    Peeters M, Price TJ, Cervantes A. Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer. J Clin Oncol 2010;28:47064713.

    • Search Google Scholar
    • Export Citation
  • 37.

    Petrelli N, Herrera L, Rustum Y. A prospective randomized trial of 5-fluorouracil versus 5-fluorouracil and high-dose leucovorin versus 5-fluorouracil and methotrexate in previously untreated patients with advanced colorectal carcinoma. J Clin Oncol 1987;5:15591565.

    • Search Google Scholar
    • Export Citation
  • 38.

    Reidy DL, Chung KY, Timoney JP. Bevacizumab 5 mg/kg can be infused safely over 10 minutes. J Clin Oncol 2007;25:26912695.

  • 39.

    Saltz LB, Clarke S, Diaz-Rubio E. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol 2008;26:20132019.

    • Search Google Scholar
    • Export Citation
  • 40.

    Souglakos J, Androulakis N, Syrigos K. FOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin and irinotecan) vs FOLFIRI (folinic acid, 5-fluorouracil and irinotecan) as first-line treatment in metastatic colorectal cancer (MCC): a multicentre randomised phase III trial from the Hellenic Oncology Research Group (HORG). Br J Cancer 2006;94:798805.

    • Search Google Scholar
    • Export Citation
  • 41.

    Tol J, Koopman M, Cats A. Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer. N Engl J Med 2009;360:563572.

  • 42.

    Van Cutsem E. Challenges in the use of epidermal growth factor receptor inhibitors in colorectal cancer. Oncologist 2006;11:10101017.

  • 43.

    Van Cutsem E, Hoff PM, Harper P. Oral capecitabine vs intravenous 5-fluorouracil and leucovorin: integrated efficacy data and novel analyses from two large, randomised, phase III trials. Br J Cancer 2004;90:11901197.

    • Search Google Scholar
    • Export Citation
  • 44.

    Van Cutsem E, Kohne CH, Hitre E. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 2009;360:14081417.

    • Search Google Scholar
    • Export Citation
  • 45.

    Van Cutsem E, Peeters M, Siena S. Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol 2007;25:16581664.

    • Search Google Scholar
    • Export Citation
  • 46.

    Van Cutsem E, Twelves C, Cassidy J. Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study. J Clin Oncol 2001;19:40974106.

    • Search Google Scholar
    • Export Citation
  • 47.

    Van Cutsem E, Tabernero J, Lakomy R. Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen. J Clin Oncol 2012;30:34993506.

    • Search Google Scholar
    • Export Citation
  • 48.

    Wolmark N, Rockette H, Fisher B. The benefit of leucovorin-modulated fluorouracil as postoperative adjuvant therapy for primary colon cancer: results from National Surgical Adjuvant Breast and Bowel Project protocol C-03. J Clin Oncol 1993;11:18791887.

    • Search Google Scholar
    • Export Citation
  • 49.

    Lentz F, Tran A, Rey E. Pharmacogenomics of fluorouracil, irinotecan, and oxaliplatin in hepatic metastases of colorectal cancer: clinical implications. Am J Pharmacogenomics 2005;5:2133.

    • Search Google Scholar
    • Export Citation
  • 50.

    O'Dwyer PJ. The present and future of angiogenesis-directed treatments of colorectal cancer. Oncologist 2006;11:992998.

  • 51.

    Raymond E, Faivre S, Woynarowski JM, Chaney SG. Oxaliplatin: mechanism of action and antineoplastic activity. Semin Oncol 1998;25:412.

  • 52.

    Rothenberg ML, Blanke CD. Topoisomerase I inhibitors in the treatment of colorectal cancer. Semin Oncol 1999;26:632639.

  • 53.

    Tournigand C, Andre T, Achille E. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 2004;22:229237.

    • Search Google Scholar
    • Export Citation
  • 54.

    Cassidy J, Tabernero J, Twelves C. XELOX (capecitabine plus oxaliplatin): active first-line therapy for patients with metastatic colorectal cancer. J Clin Oncol 2004;22:20842091.

    • Search Google Scholar
    • Export Citation
  • 55.

    Porschen R, Arkenau HT, Kubicka S. Phase III study of capecitabine plus oxaliplatin compared with fluorouracil and leucovorin plus oxaliplatin in metastatic colorectal cancer: a final report of the AIO Colorectal Study Group. J Clin Oncol 2007;25:42174223.

    • Search Google Scholar
    • Export Citation
  • 56.

    Kirstein MM, Lange A, Prenzler A. Targeted therapies in metastatic colorectal cancer: a systematic review and assessment of currently available data. Oncologist 2014;19:11561168.

    • Search Google Scholar
    • Export Citation
  • 57.

    Ducreux M, Malka D, Mendiboure J. Sequential versus combination chemotherapy for the treatment of advanced colorectal cancer (FFCD 2000-05): an open-label, randomised, phase 3 trial. Lancet Oncol 2011;12:10321044.

    • Search Google Scholar
    • Export Citation
  • 58.

    Koopman M, Antonini NF, Douma J. Sequential versus combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in advanced colorectal cancer (CAIRO): a phase III randomised controlled trial. Lancet 2007;370:135142.

    • Search Google Scholar
    • Export Citation
  • 59.

    Seymour MT, Maughan TS, Ledermann JA. Different strategies of sequential and combination chemotherapy for patients with poor prognosis advanced colorectal cancer (MRC FOCUS): a randomised controlled trial. Lancet 2007;370:143152.

    • Search Google Scholar
    • Export Citation
  • 60.

    Grothey A, Sargent D, Goldberg RM, Schmoll HJ. Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment. J Clin Oncol 2004;22:12091214.

    • Search Google Scholar
    • Export Citation
  • 61.

    Sargent DJ, Kohne CH, Sanoff HK. Pooled safety and efficacy analysis examining the effect of performance status on outcomes in nine first-line treatment trials using individual data from patients with metastatic colorectal cancer. J Clin Oncol 2009;27:19481955.

    • Search Google Scholar
    • Export Citation
  • 62.

    Simkens LH, van Tinteren H, May A. Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): a phase 3 randomised controlled trial of the Dutch Colorectal Cancer Group. Lancet 2015;385:18431852.

    • Search Google Scholar
    • Export Citation
  • 63.

    Hegewisch-Becker S, Graeven U, Lerchenmuller CA. Maintenance strategies after first-line oxaliplatin plus fluoropyrimidine plus bevacizumab for patients with metastatic colorectal cancer (AIO 0207): a randomised, non-inferiority, open-label, phase 3 trial. Lancet Oncol 2015;16:13551369.

    • Search Google Scholar
    • Export Citation
  • 64.

    Koeberle D, Betticher DC, von Moos R. Bevacizumab continuation versus no continuation after first-line chemotherapy plus bevacizumab in patients with metastatic colorectal cancer: a randomized phase III non-inferiority trial (SAKK 41/06). Ann Oncol 2015;26:709714.

    • Search Google Scholar
    • Export Citation
  • 65.

    Tournigand C, Chibaudel B, Samson B. Bevacizumab with or without erlotinib as maintenance therapy in patients with metastatic colorectal cancer (GERCOR DREAM; OPTIMOX3): a randomised, open-label, phase 3 trial. Lancet Oncol 2015;16:14931505.

    • Search Google Scholar
    • Export Citation
  • 66.

    Hagman H, Frodin JE, Berglund A. A randomized study of KRAS-guided maintenance therapy with bevacizumab, erlotinib or metronomic capecitabine after first-line induction treatment of metastatic colorectal cancer: the Nordic ACT2 trial. Ann Oncol 2016;27:140147.

    • Search Google Scholar
    • Export Citation
  • 67.

    Xu W, Gong Y, Kuang M. Survival benefit and safety of bevacizumab in combination with erlotinib as maintenance therapy in patients with metastatic colorectal cancer: a meta-analysis. Clin Drug Investig 2017;37:155165.

    • Search Google Scholar
    • Export Citation
  • 68.

    Luo HY, Li YH, Wang W. Single-agent capecitabine as maintenance therapy after induction of XELOX (or FOLFOX) in first-line treatment of metastatic colorectal cancer: randomized clinical trial of efficacy and safety. Ann Oncol 2016;27:10741081.

    • Search Google Scholar
    • Export Citation
  • 69.

    AVASTIN [package insert]. South San Francisco, CA: Genentech, Inc.; 2015.

  • 70.

    Hurwitz H, Fehrenbacher L, Novotny W. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350:23352342.

    • Search Google Scholar
    • Export Citation
  • 71.

    Kabbinavar F, Hurwitz HI, Fehrenbacher L. Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol 2003;21:6065.

    • Search Google Scholar
    • Export Citation
  • 72.

    Kabbinavar FF, Schulz J, McCleod M. Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial. J Clin Oncol 2005;23:36973705.

    • Search Google Scholar
    • Export Citation
  • 73.

    Petrelli F, Borgonovo K, Cabiddu M. FOLFIRI-bevacizumab as first-line chemotherapy in 3500 patients with advanced colorectal cancer: a pooled analysis of 29 published trials. Clin Colorectal Cancer 2013;12:145151.

    • Search Google Scholar
    • Export Citation
  • 74.

    Hurwitz HI, Bekaii-Saab TS, Bendell JC. Safety and effectiveness of bevacizumab treatment for metastatic colorectal cancer: final results from the Avastin((R)) Registry - Investigation of Effectiveness and Safety (ARIES) observational cohort study. Clin Oncol (R Coll Radiol) 2014;26:323332.

    • Search Google Scholar
    • Export Citation
  • 75.

    Fourrier-Reglat A, Smith D, Rouyer M. Survival outcomes of bevacizumab in first-line metastatic colorectal cancer in a real-life setting: results of the ETNA cohort. Target Oncol 2014;9:311319.

    • Search Google Scholar
    • Export Citation
  • 76.

    Botrel TE, Clark LG, Paladini L, Clark OA. Efficacy and safety of bevacizumab plus chemotherapy compared to chemotherapy alone in previously untreated advanced or metastatic colorectal cancer: a systematic review and meta-analysis. BMC Cancer 2016;16:677.

    • Search Google Scholar
    • Export Citation
  • 77.

    Cao Y, Tan A, Gao F. A meta-analysis of randomized controlled trials comparing chemotherapy plus bevacizumab with chemotherapy alone in metastatic colorectal cancer. Int J Colorectal Dis 2009;24:677685.

    • Search Google Scholar
    • Export Citation
  • 78.

    Hu W, Xu W, Liao X, He H. Bevacizumab in combination with first-line chemotherapy in patients with metastatic colorectal cancer: a meta-analysis. Minerva Chir 2015;70:451458.

    • Search Google Scholar
    • Export Citation
  • 79.

    Hurwitz HI, Tebbutt NC, Kabbinavar F. Efficacy and safety of bevacizumab in metastatic colorectal cancer: pooled analysis from seven randomized controlled trials. Oncologist 2013;18:10041012.

    • Search Google Scholar
    • Export Citation
  • 80.

    Loupakis F, Bria E, Vaccaro V. Magnitude of benefit of the addition of bevacizumab to first-line chemotherapy for metastatic colorectal cancer: meta-analysis of randomized clinical trials. J Exp Clin Cancer Res 2010;29:58.

    • Search Google Scholar
    • Export Citation
  • 81.

    Lv C, Wu S, Zheng D. The efficacy of additional bevacizumab to cytotoxic chemotherapy regimens for the treatment of colorectal cancer: an updated meta-analysis for randomized trials. Cancer Biother Radiopharm 2013;28:501509.

    • Search Google Scholar
    • Export Citation
  • 82.

    Qu CY, Zheng Y, Zhou M. Value of bevacizumab in treatment of colorectal cancer: a meta-analysis. World J Gastroenterol 2015;21:50725080.

  • 83.

    Welch S, Spithoff K, Rumble RB, Maroun J. Bevacizumab combined with chemotherapy for patients with advanced colorectal cancer: a systematic review. Ann Oncol 2010;21:11521162.

    • Search Google Scholar
    • Export Citation
  • 84.

    Zhang G, Zhou X, Lin C. Efficacy of chemotherapy plus bevacizumab as first-line therapy in patients with metastatic colorectal cancer: a meta-analysis and up-date. Int J Clin Exp Med 2015;8:14341445.

    • Search Google Scholar
    • Export Citation
  • 85.

    Macedo LT, da Costa Lima AB, Sasse AD. Addition of bevacizumab to first-line chemotherapy in advanced colorectal cancer: a systematic review and meta-analysis, with emphasis on chemotherapy subgroups. BMC Cancer 2012;12:89.

    • Search Google Scholar
    • Export Citation
  • 86.

    Meyerhardt JA, Li L, Sanoff HK. Effectiveness of bevacizumab with first-line combination chemotherapy for Medicare patients with stage IV colorectal cancer. J Clin Oncol 2012;30:608615.

    • Search Google Scholar
    • Export Citation
  • 87.

    Hartmann H, Muller J, Marschner N. Is there a difference in demography and clinical characteristics in patients treated with and without bevacizumab? J Clin Oncol 2012;30:33173318; author reply 3318.

    • Search Google Scholar
    • Export Citation
  • 88.

    Hurwitz HI, Lyman GH. Registries and randomized trials in assessing the effects of bevacizumab in colorectal cancer: is there a common theme? J Clin Oncol 2012;30:580581.

    • Search Google Scholar
    • Export Citation
  • 89.

    Allegra CJ, Yothers G, O'Connell MJ. Phase III trial assessing bevacizumab in stages II and III carcinoma of the colon: results of NSABP protocol C-08. J Clin Oncol 2011;29:1116.

    • Search Google Scholar
    • Export Citation
  • 90.

    de Gramont A, Van Cutsem E, Schmoll HJ. Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (AVANT): a phase 3 randomised controlled trial. Lancet Oncol 2012;13:12251233.

    • Search Google Scholar
    • Export Citation
  • 91.

    Ranpura V, Hapani S, Wu S. Treatment-related mortality with bevacizumab in cancer patients: a meta-analysis. JAMA 2011;305:487494.

  • 92.

    Hurwitz HI, Saltz LB, Van Cutsem E. Venous thromboembolic events with chemotherapy plus bevacizumab: a pooled analysis of patients in randomized phase II and III studies. J Clin Oncol 2011;29:17571764.

    • Search Google Scholar
    • Export Citation
  • 93.

    Dai F, Shu L, Bian Y. Safety of bevacizumab in treating metastatic colorectal cancer: a systematic review and meta-analysis of all randomized clinical trials. Clin Drug Investig 2013;33:779788.

    • Search Google Scholar
    • Export Citation
  • 94.

    Hochster HS, Hart LL, Ramanathan RK. Safety and efficacy of oxaliplatin and fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer: results of the TREE Study. J Clin Oncol 2008;26:35233529.

    • Search Google Scholar
    • Export Citation
  • 95.

    Scappaticci FA, Fehrenbacher L, Cartwright T. Surgical wound healing complications in metastatic colorectal cancer patients treated with bevacizumab. J Surg Oncol 2005;91:173180.

    • Search Google Scholar
    • Export Citation
  • 96.

    Cannistra SA, Matulonis UA, Penson RT. Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer. J Clin Oncol 2007;25:51805186.

    • Search Google Scholar
    • Export Citation
  • 97.

    Gruenberger B, Tamandl D, Schueller J. Bevacizumab, capecitabine, and oxaliplatin as neoadjuvant therapy for patients with potentially curable metastatic colorectal cancer. J Clin Oncol 2008;26:18301835.

    • Search Google Scholar
    • Export Citation
  • 98.

    Reddy SK, Morse MA, Hurwitz HI. Addition of bevacizumab to irinotecan- and oxaliplatin-based preoperative chemotherapy regimens does not increase morbidity after resection of colorectal liver metastases. J Am Coll Surg 2008;206:969106.

    • Search Google Scholar
    • Export Citation
  • 99.

    Miles D, Harbeck N, Escudier B. Disease course patterns after discontinuation of bevacizumab: pooled analysis of randomized phase III trials. J Clin Oncol 2011;29:8388.

    • Search Google Scholar
    • Export Citation
  • 100.

    Miles DW. Reply to P. Potemski. J Clin Oncol 2011;29:e386.

  • 101.

    Potemski P. Is the postprogression survival time really not shortened in the bevacizumab-containing arms of phase III clinical trials? J Clin Oncol 2011;29:e384385.

    • Search Google Scholar
    • Export Citation
  • 102.

    Cetuximab [package insert]. Branchburg, NJ: ImClone Systems Incorporated; 2015.

  • 103.

    Vectibix [package insert]. Thousand Oaks, CA: Amgen Inc.; 2015.

  • 104.

    Pietrantonio F, Cremolini C, Petrelli F. First-line anti-EGFR monoclonal antibodies in panRAS wild-type metastatic colorectal cancer: a systematic review and meta-analysis. Crit Rev Oncol Hematol 2015;96:156166.

    • Search Google Scholar
    • Export Citation
  • 105.

    Sorich MJ, Wiese MD, Rowland A. Extended RAS mutations and anti-EGFR monoclonal antibody survival benefit in metastatic colorectal cancer: a meta-analysis of randomized, controlled trials. Ann Oncol 2015;26:1321.

    • Search Google Scholar
    • Export Citation
  • 106.

    Helbling D, Borner M. Successful challenge with the fully human EGFR antibody panitumumab following an infusion reaction with the chimeric EGFR antibody cetuximab. Ann Oncol 2007;18:963964.

    • Search Google Scholar
    • Export Citation
  • 107.

    Heun J, Holen K. Treatment with panitumumab after a severe infusion reaction to cetuximab in a patient with metastatic colorectal cancer: a case report. Clin Colorectal Cancer 2007;6:529531.

    • Search Google Scholar
    • Export Citation
  • 108.

    Resch G, Schaberl-Moser R, Kier P. Infusion reactions to the chimeric EGFR inhibitor cetuximab—change to the fully human anti-EGFR monoclonal antibody panitumumab is safe. Ann Oncol 2011;22:486487.

    • Search Google Scholar
    • Export Citation
  • 109.

    Jonker DJ, O'Callaghan CJ, Karapetis CS. Cetuximab for the treatment of colorectal cancer. N Engl J Med 2007;357:20402048.

  • 110.

    Lievre A, Bachet JB, Boige V. KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J Clin Oncol 2008;26:374379.

    • Search Google Scholar
    • Export Citation
  • 111.

    Petrelli F, Borgonovo K, Barni S. The predictive role of skin rash with cetuximab and panitumumab in colorectal cancer patients: a systematic review and meta-analysis of published trials. Target Oncol 2013;8:173181.

    • Search Google Scholar
    • Export Citation
  • 112.

    Stintzing S, Kapaun C, Laubender RP. Prognostic value of cetuximab-related skin toxicity in metastatic colorectal cancer patients and its correlation with parameters of the epidermal growth factor receptor signal transduction pathway: results from a randomized trial of the GERMAN AIO CRC Study Group. Int J Cancer 2013;132:236245.

    • Search Google Scholar
    • Export Citation
  • 113.

    Van Cutsem E, Tejpar S, Vanbeckevoort D. Intrapatient cetuximab dose escalation in metastatic colorectal cancer according to the grade of early skin reactions: the randomized EVEREST study. J Clin Oncol 2012;30:28612868.

    • Search Google Scholar
    • Export Citation
  • 114.

    Burtness B, Anadkat M, Basti S. NCCN Task Force Report: management of dermatologic and other toxicities associated with EGFR inhibition in patients with cancer. J Natl Compr Canc Netw 2009;7(Suppl 1):S521; quiz S22–24.

    • Search Google Scholar
    • Export Citation
  • 115.

    Petrelli F, Cabiddu M, Borgonovo K, Barni S. Risk of venous and arterial thromboembolic events associated with anti-EGFR agents: a meta-analysis of randomized clinical trials. Ann Oncol 2012;23:16721679.

    • Search Google Scholar
    • Export Citation
  • 116.

    Zhang D, Ye J, Xu T, Xiong B. Treatment related severe and fatal adverse events with cetuximab in colorectal cancer patients: a meta-analysis. J Chemother 2013;25:170175.

    • Search Google Scholar
    • Export Citation
  • 117.

    Hecht JR, Mitchell E, Chidiac T. A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer. J Clin Oncol 2009;27:672680.

    • Search Google Scholar
    • Export Citation
  • 118.

    Brule SY, Jonker DJ, Karapetis CS. Location of colon cancer (right-sided versus left-sided) as a prognostic factor and a predictor of benefit from cetuximab in NCIC CO.17. Eur J Cancer 2015;51:14051414.

    • Search Google Scholar
    • Export Citation
  • 119.

    Moretto R, Cremolini C, Rossini D. Location of primary tumor and benefit from anti-epidermal growth factor receptor monoclonal antibodies in patients with RAS and BRAF wild-type metastatic colorectal cancer. Oncologist 2016;21:988994.

    • Search Google Scholar
    • Export Citation
  • 120.

    Loupakis F, Yang D, Yau L. Primary tumor location as a prognostic factor in metastatic colorectal cancer. J Natl Cancer Inst 2015;107:doi: 10.1093/jnci/dju427.

    • Search Google Scholar
    • Export Citation
  • 121.

    Lee MS, Advani SM, Morris J. Association of primary (1°) site and molecular features with progression-free survival (PFS) and overall survival (OS) of metastatic colorectal cancer (mCRC) after anti-epidermal growth factor receptor (αEGFR) therapy [abstract]. J Clin Oncol 2016;34(Suppl):Abstract 3506.

    • Search Google Scholar
    • Export Citation
  • 122.

    Chen KH, Shao YY, Chen HM. Primary tumor site is a useful predictor of cetuximab efficacy in the third-line or salvage treatment of KRAS wild-type (exon 2 non-mutant) metastatic colorectal cancer: a nationwide cohort study. BMC Cancer 2016;16:327.

    • Search Google Scholar
    • Export Citation
  • 123.

    Warschkow R, Sulz MC, Marti L. Better survival in right-sided versus left-sided stage I - III colon cancer patients. BMC Cancer 2016;16:554.

  • 124.

    Schrag D, Weng S, Brooks G. The relationship between primary tumor sidedness and prognosis in colorectal cancer [abstract]. J Clin Oncol 2016;34(Suppl):Abstract 3505.

    • Search Google Scholar
    • Export Citation
  • 125.

    Venook AP, Niedzwiecki D, Innocenti F. Impact of primary (1°) tumor location on overall survival (OS) and progression-free survival (PFS) in patients (pts) with metastatic colorectal cancer (mCRC): analysis of CALGB/SWOG 80405 (Alliance) [abstract]. J Clin Oncol 2016;34(Suppl):Abstract 3504.

    • Search Google Scholar
    • Export Citation
  • 126.

    Venook AP, Niedzwiecki D, Innocenti F. Impact of primary (1°) tumor location on Overall Survival (OS) and Progression Free Survival (PFS) in patients (pts) with metastatic colorectal cancer (mCRC): analysis of All RAS wt patients on CALGB / SWOG 80405 (Alliance) [abstract]. Presented at ESMO Congress 2016; October 7–11, 2016; Copenhagen, Denmark.

    • Search Google Scholar
    • Export Citation
  • 127.

    Antonacopoulou AG, Tsamandas AC, Petsas T. EGFR, HER-2 and COX-2 levels in colorectal cancer. Histopathology 2008;53:698706.

  • 128.

    McKay JA, Murray LJ, Curran S. Evaluation of the epidermal growth factor receptor (EGFR) in colorectal tumours and lymph node metastases. Eur J Cancer 2002;38:22582264.

    • Search Google Scholar
    • Export Citation
  • 129.

    Spano JP, Lagorce C, Atlan D. Impact of EGFR expression on colorectal cancer patient prognosis and survival. Ann Oncol 2005;16:102108.

  • 130.

    Yen LC, Uen YH, Wu DC. Activating KRAS mutations and overexpression of epidermal growth factor receptor as independent predictors in metastatic colorectal cancer patients treated with cetuximab. Ann Surg 2010;251:254260.

    • Search Google Scholar
    • Export Citation
  • 131.

    Hecht JR, Mitchell E, Neubauer MA. Lack of correlation between epidermal growth factor receptor status and response to Panitumumab monotherapy in metastatic colorectal cancer. Clin Cancer Res 2010;16:22052213.

    • Search Google Scholar
    • Export Citation
  • 132.

    Saltz LB, Meropol NJ, Loehrer PJ. Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol 2004;22:12011208.

    • Search Google Scholar
    • Export Citation
  • 133.

    Baselga J, Rosen N. Determinants of RASistance to anti-epidermal growth factor receptor agents. J Clin Oncol 2008;26:15821584.

  • 134.

    Bokemeyer C, Bondarenko I, Makhson A. Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J Clin Oncol 2009;27:663671.

    • Search Google Scholar
    • Export Citation
  • 135.

    De Roock W, Piessevaux H, De Schutter J. KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab. Ann Oncol 2008;19:508515.

    • Search Google Scholar
    • Export Citation
  • 136.

    Karapetis CS, Khambata-Ford S, Jonker DJ. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 2008;359:17571765.

    • Search Google Scholar
    • Export Citation
  • 137.

    Khambata-Ford S, Garrett CR, Meropol NJ. Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab. J Clin Oncol 2007;25:32303237.

    • Search Google Scholar
    • Export Citation
  • 138.

    Tejpar S, Celik I, Schlichting M. Association of KRAS G13D tumor mutations with outcome in patients with metastatic colorectal cancer treated with first-line chemotherapy with or without cetuximab. J Clin Oncol 2012;30:35703577.

    • Search Google Scholar
    • Export Citation
  • 139.

    Douillard JY, Oliner KS, Siena S. Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. N Engl J Med 2013;369:10231034.

  • 140.

    Allegra CJ, Rumble RB, Hamilton SR. Extended RAS gene mutation testing in metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy: American Society of Clinical Oncology provisional clinical opinion update 2015. J Clin Oncol 2016;34:179185.

    • Search Google Scholar
    • Export Citation
  • 141.

    Artale S, Sartore-Bianchi A, Veronese SM. Mutations of KRAS and BRAF in primary and matched metastatic sites of colorectal cancer. J Clin Oncol 2008;26:42174219.

    • Search Google Scholar
    • Export Citation
  • 142.

    Etienne-Grimaldi MC, Formento JL, Francoual M. K-Ras mutations and treatment outcome in colorectal cancer patients receiving exclusive fluoropyrimidine therapy. Clin Cancer Res 2008;14:48304835.

    • Search Google Scholar
    • Export Citation
  • 143.

    Knijn N, Mekenkamp LJ, Klomp M. KRAS mutation analysis: a comparison between primary tumours and matched liver metastases in 305 colorectal cancer patients. Br J Cancer 2011;104:10201026.

    • Search Google Scholar
    • Export Citation
  • 144.

    Wang HL, Lopategui J, Amin MB, Patterson SD. KRAS mutation testing in human cancers: the pathologist's role in the era of personalized medicine. Adv Anat Pathol 2010;17:2332.

    • Search Google Scholar
    • Export Citation
  • 145.

    Monzon FA, Ogino S, Hammond MEH. The role of KRAS mutation testing in the management of patients with metastatic colorectal cancer. Arch Pathol Lab Med 2009;133:16001606.

    • Search Google Scholar
    • Export Citation
  • 146.

    Roth AD, Tejpar S, Delorenzi M. Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial. J Clin Oncol 2010;28:466474.

    • Search Google Scholar
    • Export Citation
  • 147.

    Dahabreh IJ, Terasawa T, Castaldi PJ, Trikalinos TA. Systematic review: anti-epidermal growth factor receptor treatment effect modification by KRAS mutations in advanced colorectal cancer. Ann Intern Med 2011;154:3749.

    • Search Google Scholar
    • Export Citation
  • 148.

    Yoon HH, Tougeron D, Shi Q. KRAS codon 12 and 13 mutations in relation to disease-free survival in BRAF-wild-type stage III colon cancers from an adjuvant chemotherapy trial (N0147 alliance). Clin Cancer Res 2014;20:30333043.

    • Search Google Scholar
    • Export Citation
  • 149.

    De Roock W, Jonker DJ, Di Nicolantonio F. Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab. JAMA 2010;304:18121820.

    • Search Google Scholar
    • Export Citation
  • 150.

    Peeters M, Douillard JY, Van Cutsem E. Mutant KRAS codon 12 and 13 alleles in patients with metastatic colorectal cancer: assessment as prognostic and predictive biomarkers of response to panitumumab. J Clin Oncol 2013;31:759765.

    • Search Google Scholar
    • Export Citation
  • 151.

    Schirripa M, Loupakis F, Lonardi S. Phase II study of single-agent cetuximab in KRAS G13D mutant metastatic colorectal cancer. Ann Oncol 2015;26:2503.

    • Search Google Scholar
    • Export Citation
  • 152.

    Segelov E, Thavaneswaran S, Waring PM. Response to cetuximab with or without irinotecan in patients with refractory metastatic colorectal cancer harboring the KRAS G13D mutation: Australasian Gastro-Intestinal Trials Group ICECREAM study. J Clin Oncol 2016;34:22582264.

    • Search Google Scholar
    • Export Citation
  • 153.

    Price TJ, Bruhn MA, Lee CK. Correlation of extended RAS and PIK3CA gene mutation status with outcomes from the phase III AGITG MAX study involving capecitabine alone or in combination with bevacizumab plus or minus mitomycin C in advanced colorectal cancer. Br J Cancer 2015;112:963970.

    • Search Google Scholar
    • Export Citation
  • 154.

    Heinemann V, von Weikersthal LF, Decker T. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial. Lancet Oncol 2014;15:10651075.

    • Search Google Scholar
    • Export Citation
  • 155.

    Tol J, Nagtegaal ID, Punt CJ. BRAF mutation in metastatic colorectal cancer. N Engl J Med 2009;361:9899.

  • 156.

    Van Cutsem E, Kohne CH, Lang I. Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. J Clin Oncol 2011;29:20112019.

    • Search Google Scholar
    • Export Citation
  • 157.

    Maughan TS, Adams RA, Smith CG. Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial. Lancet 2011;377:21032114.

    • Search Google Scholar
    • Export Citation
  • 158.

    Davies H, Bignell GR, Cox C. Mutations of the BRAF gene in human cancer. Nature 2002;417:949954.

  • 159.

    Ikenoue T, Hikiba Y, Kanai F. Functional analysis of mutations within the kinase activation segment of B-Raf in human colorectal tumors. Cancer Res 2003;63:81328137.

    • Search Google Scholar
    • Export Citation
  • 160.

    Wan PT, Garnett MJ, Roe SM. Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell 2004;116:855867.

  • 161.

    Bokemeyer C, Cutsem EV, Rougier P. Addition of cetuximab to chemotherapy as first-line treatment for KRAS wild-type metastatic colorectal cancer: pooled analysis of the CRYSTAL and OPUS randomised clinical trials. Eur J Cancer 2012;48:14661475.

    • Search Google Scholar
    • Export Citation
  • 162.

    Di Nicolantonio F, Martini M, Molinari F. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J Clin Oncol 2008;26:57055712.

    • Search Google Scholar
    • Export Citation
  • 163.

    Laurent-Puig P, Cayre A, Manceau G. Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer. J Clin Oncol 2009;27:59245930.

    • Search Google Scholar
    • Export Citation
  • 164.

    Loupakis F, Ruzzo A, Cremolini C. KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer. Br J Cancer 2009;101:715721.

    • Search Google Scholar
    • Export Citation
  • 165.

    De Roock W, Claes B, Bernasconi D. Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncol 2010;11:753762.

    • Search Google Scholar
    • Export Citation
  • 166.

    Seymour MT, Brown SR, Middleton G. Panitumumab and irinotecan versus irinotecan alone for patients with KRAS wild-type, fluorouracil-resistant advanced colorectal cancer (PICCOLO): a prospectively stratified randomised trial. Lancet Oncol 2013;14:749759.

    • Search Google Scholar
    • Export Citation
  • 167.

    Pietrantonio F, Petrelli F, Coinu A. Predictive role of BRAF mutations in patients with advanced colorectal cancer receiving cetuximab and panitumumab: a meta-analysis. Eur J Cancer 2015;51:587594.

    • Search Google Scholar
    • Export Citation
  • 168.

    Rowland A, Dias MM, Wiese MD. Meta-analysis of BRAF mutation as a predictive biomarker of benefit from anti-EGFR monoclonal antibody therapy for RAS wild-type metastatic colorectal cancer. Br J Cancer 2015;112:18881894.

    • Search Google Scholar
    • Export Citation
  • 169.

    Chen D, Huang JF, Liu K. BRAFV600E mutation and its association with clinicopathological features of colorectal cancer: a systematic review and meta-analysis. PLoS One 2014;9:e90607.

    • Search Google Scholar
    • Export Citation
  • 170.

    Price TJ, Hardingham JE, Lee CK. Impact of KRAS and BRAF gene mutation status on outcomes from the phase III AGITG MAX trial of capecitabine alone or in combination with bevacizumab and mitomycin in advanced colorectal cancer. J Clin Oncol 2011;29:26752682.

    • Search Google Scholar
    • Export Citation
  • 171.

    Safaee Ardekani G, Jafarnejad SM, Tan L. The prognostic value of BRAF mutation in colorectal cancer and melanoma: a systematic review and meta-analysis. PLoS One 2012;7:e47054.

    • Search Google Scholar
    • Export Citation
  • 172.

    Samowitz WS, Sweeney C, Herrick J. Poor survival associated with the BRAF V600E mutation in microsatellite-stable colon cancers. Cancer Res 2005;65:60636069.

    • Search Google Scholar
    • Export Citation
  • 173.

    Saridaki Z, Papadatos-Pastos D, Tzardi M. BRAF mutations, microsatellite instability status and cyclin D1 expression predict metastatic colorectal patients' outcome. Br J Cancer 2010;102:17621768.

    • Search Google Scholar
    • Export Citation
  • 174.

    Xu Q, Xu AT, Zhu MM. Predictive and prognostic roles of BRAF mutation in patients with metastatic colorectal cancer treated with anti-epidermal growth factor receptor monoclonal antibodies: a meta-analysis. J Dig Dis 2013;14:409416.

    • Search Google Scholar
    • Export Citation
  • 175.

    Clancy C, Burke JP, Kalady MF, Coffey JC. BRAF mutation is associated with distinct clinicopathological characteristics in colorectal cancer: a systematic review and meta-analysis. Colorectal Dis 2013;15:e711718.

    • Search Google Scholar
    • Export Citation
  • 176.

    Santini D, Spoto C, Loupakis F. High concordance of BRAF status between primary colorectal tumours and related metastatic sites: implications for clinical practice. Ann Oncol 2010;21:1565.

    • Search Google Scholar
    • Export Citation
  • 177.

    Sartore-Bianchi A, Trusolino L, Martino C. Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial. Lancet Oncol 2016;17:738746.

    • Search Google Scholar
    • Export Citation
  • 178.

    Raghav KPS, Overman MJ, Yu R. HER2 amplification as a negative predictive biomarker for anti-epidermal growth factor receptor antibody therapy in metastatic colorectal cancer [abstract]. J Clin Oncol 2016;34(Suppl):Abstract 3517.

    • Search Google Scholar
    • Export Citation
  • 179.

    Valtorta E, Martino C, Sartore-Bianchi A. Assessment of a HER2 scoring system for colorectal cancer: results from a validation study. Mod Pathol 2015;28:14811491.

    • Search Google Scholar
    • Export Citation
  • 180.

    Hurwitz H, Hainsworth JD, Swanton C. Targeted therapy for gastrointestinaI (GI) tumors based on molecular profiles: early results from MyPathway, an open-label phase IIa basket study in patients with advanced solid tumors [abstract]. J Clin Oncol 2016;34(Suppl):Abstract 653.

    • Search Google Scholar
    • Export Citation
  • 181.

    Wu SW, Ma CC, Li WH. Does overexpression of HER-2 correlate with clinicopathological characteristics and prognosis in colorectal cancer? Evidence from a meta-analysis. Diagn Pathol 2015;10:144.

    • Search Google Scholar
    • Export Citation
  • 182.

    Martin V, Landi L, Molinari F. HER2 gene copy number status may influence clinical efficacy to anti-EGFR monoclonal antibodies in metastatic colorectal cancer patients. Br J Cancer 2013;108:668675.

    • Search Google Scholar
    • Export Citation
  • 183.

    Lang I, Kohne CH, Folprecht G. Quality of life analysis in patients with KRAS wild-type metastatic colorectal cancer treated first-line with cetuximab plus irinotecan, fluorouracil and leucovorin. Eur J Cancer 2013;49:439448.

    • Search Google Scholar
    • Export Citation
  • 184.

    Van Cutsem E, Lenz HJ, Kohne CH. Fluorouracil, leucovorin, and irinotecan plus cetuximab treatment and RAS mutations in colorectal cancer. J Clin Oncol 2015;33:692700.

    • Search Google Scholar
    • Export Citation
  • 185.

    Mitchell EP, Piperdi B, Lacouture ME. The efficacy and safety of panitumumab administered concomitantly with FOLFIRI or Irinotecan in second-line therapy for metastatic colorectal cancer: the secondary analysis from STEPP (Skin Toxicity Evaluation Protocol With Panitumumab) by KRAS status. Clin Colorectal Cancer 2011;10:333339.

    • Search Google Scholar
    • Export Citation
  • 186.

    Peeters M, Price TJ, Cervantes A. Final results from a randomized phase 3 study of FOLFIRI {+/–} panitumumab for second-line treatment of metastatic colorectal cancer. Ann Oncol 2014;25:107116.

    • Search Google Scholar
    • Export Citation
  • 187.

    Bokemeyer C, Bondarenko I, Hartmann JT. Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study. Ann Oncol 2011;22:15351546.

    • Search Google Scholar
    • Export Citation
  • 188.

    Taieb J, Maughan T, Bokemeyer C. Cetuximab combined with infusional 5-fluorouracil/folinic acid (5-FU/FA) and oxaliplatin in metastatic colorectal cancer (mCRC): a pooled analysis of COIN and OPUS study data [abstract]. J Clin Oncol 2012;30(Suppl):Abstract 3574.

    • Search Google Scholar
    • Export Citation
  • 189.

    Tveit KM, Guren T, Glimelius B. Phase III trial of cetuximab with continuous or intermittent fluorouracil, leucovorin, and oxaliplatin (Nordic FLOX) versus FLOX alone in first-line treatment of metastatic colorectal cancer: the NORDIC-VII study. J Clin Oncol 2012;30:17551762.

    • Search Google Scholar
    • Export Citation
  • 190.

    Venook AP, Niedzwiecki D, Lenz HJ. CALGB/SWOG 80405: phase III trial of irinotecan/5-FU/leucovorin (FOLFIRI) or oxaliplatin/5-FU/leucovorin (mFOLFOX6) with bevacizumab (BV) or cetuximab (CET) for patients (pts) with KRAS wild-type (wt) untreated metastatic adenocarcinoma of the colon or rectum (MCRC) [abstract]. J Clin Oncol 2014;32(Suppl):Abstract LBA3.

    • Search Google Scholar
    • Export Citation
  • 191.

    Primrose J, Falk S, Finch-Jones M. Systemic chemotherapy with or without cetuximab in patients with resectable colorectal liver metastasis: the New EPOC randomised controlled trial. Lancet Oncol 2014;15:601611.

    • Search Google Scholar
    • Export Citation
  • 192.

    Modest DP, Stintzing S, von Weikersthal LF. Impact of subsequent therapies on outcome of the FIRE-3/AIO KRK0306 trial: first-line therapy with FOLFIRI plus cetuximab or bevacizumab in patients with KRAS wild-type tumors in metastatic colorectal cancer. J Clin Oncol 2015;33:37183726.

    • Search Google Scholar
    • Export Citation
  • 193.

    O'Neil BH, Venook AP. Trying to understand differing results of FIRE-3 and 80405: does the first treatment matter more than others? J Clin Oncol 2015;33:36863688.

    • Search Google Scholar
    • Export Citation
  • 194.

    Schwartzberg LS, Rivera F, Karthaus M. PEAK: a randomized, multicenter phase II study of panitumumab plus modified fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) or bevacizumab plus mFOLFOX6 in patients with previously untreated, unresectable, wild-type KRAS exon 2 metastatic colorectal cancer. J Clin Oncol 2014;32:22402247.

    • Search Google Scholar
    • Export Citation
  • 195.

    Wolpin BM, Bass AJ. Managing advanced colorectal cancer: have we reached the PEAK with current therapies? J Clin Oncol 2014;32:22002202.

  • 196.

    Riesco-Martinez MC, Berry SR, Ko YJ. Cost-effectiveness analysis of different sequences of the use of epidermal growth factor receptor inhibitors for wild-type KRAS unresectable metastatic colorectal cancer. J Oncol Pract 2016;12:e710723.

    • Search Google Scholar
    • Export Citation
  • 197.

    Schrag D, Dueck AC, Naughton MJ. Cost of chemotherapy for metastatic colorectal cancer with either bevacizumab or cetuximab: economic analysis of CALGB/SWOG 80405 [abstract]. J Clin Oncol 2015;33(Suppl):Abstract 6504.

    • Search Google Scholar
    • Export Citation
  • 198.

    Hoff PM, Pazdur R, Lassere Y. Phase II study of capecitabine in patients with fluorouracil-resistant metastatic colorectal carcinoma. J Clin Oncol 2004;22:20782083.

    • Search Google Scholar
    • Export Citation
  • 199.

    Rougier P, Van Cutsem E, Bajetta E. Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer. Lancet 1998;352:14071412.

    • Search Google Scholar
    • Export Citation
  • 200.

    Kim GP, Sargent DJ, Mahoney MR. Phase III noninferiority trial comparing irinotecan with oxaliplatin, fluorouracil, and leucovorin in patients with advanced colorectal carcinoma previously treated with fluorouracil: N9841. J Clin Oncol 2009;27:28482854.

    • Search Google Scholar
    • Export Citation
  • 201.

    Segelov E, Chan D, Shapiro J. The role of biological therapy in metastatic colorectal cancer after first-line treatment: a meta-analysis of randomised trials. Br J Cancer 2014;111:11221131.

    • Search Google Scholar
    • Export Citation
  • 202.

    Hofheinz RD, Ronellenfitsch U, Kubicka S. Treatment with antiangiogenic drugs in multiple lines in patients with metastatic colorectal cancer: meta-analysis of randomized trials. Gastroenterol Res Pract 2016;2016:9189483.

    • Search Google Scholar
    • Export Citation
  • 203.

    Peeters M, Oliner K, Price TJ. Analysis of KRAS/NRAS mutations in a phase 3 study of panitumumab with FOLFIRI compared with FOLFIRI alone as second-line treatment for metastatic colorectal cancer. Clin Cancer Res 2015;21:54695479.

    • Search Google Scholar
    • Export Citation
  • 204.

    Sobrero AF, Maurel J, Fehrenbacher L. EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer. J Clin Oncol 2008;26:23112319.

    • Search Google Scholar
    • Export Citation
  • 205.

    Price TJ, Peeters M, Kim TW. Panitumumab versus cetuximab in patients with chemotherapy-refractory wild-type KRAS exon 2 metastatic colorectal cancer (ASPECCT): a randomised, multicentre, open-label, non-inferiority phase 3 study. Lancet Oncol 2014;15:569579.

    • Search Google Scholar
    • Export Citation
  • 206.

    Bennouna J, Sastre J, Arnold D. Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial. Lancet Oncol 2013;14:2937.

    • Search Google Scholar
    • Export Citation
  • 207.

    Kubicka S, Greil R, Andre T. Bevacizumab plus chemotherapy continued beyond first progression in patients with metastatic colorectal cancer previously treated with bevacizumab plus chemotherapy: ML18147 study KRAS subgroup findings. Ann Oncol 2013;24:23422349.

    • Search Google Scholar
    • Export Citation
  • 208.

    Masi G, Salvatore L, Boni L. Continuation or reintroduction of bevacizumab beyond progression to first-line therapy in metastatic colorectal cancer: final results of the randomized BEBYP trial. Ann Oncol 2015;26:724730.

    • Search Google Scholar
    • Export Citation
  • 209.

    Iwamoto S, Takahashi T, Tamagawa H. FOLFIRI plus bevacizumab as second-line therapy in patients with metastatic colorectal cancer after first-line bevacizumab plus oxaliplatin-based therapy: the randomized phase III EAGLE study. Ann Oncol 2015;26:14271433.

    • Search Google Scholar
    • Export Citation
  • 210.

    Cartwright TH, Yim YM, Yu E. Survival outcomes of bevacizumab beyond progression in metastatic colorectal cancer patients treated in US community oncology. Clin Colorectal Cancer 2012;11:238246.

    • Search Google Scholar
    • Export Citation
  • 211.

    Grothey A, Flick ED, Cohn AL. Bevacizumab exposure beyond first disease progression in patients with metastatic colorectal cancer: analyses of the ARIES observational cohort study. Pharmacoepidemiol Drug Saf 2014;23:726734.

    • Search Google Scholar
    • Export Citation
  • 212.

    Goldstein DA, El-Rayes BF. Considering efficacy and cost, where does ramucirumab fit in the management of metastatic colorectal cancer? Oncologist 2015;20:981982.

    • Search Google Scholar
    • Export Citation
  • 213.

    ZALTRAP [package insert]. Bridgewater, NJ: Regeneron Pharmaceuticals, Inc./sanofi-aventis U.S. LLC; 2016.

  • 214.

    Tabernero J, Van Cutsem E, Lakomy R. Aflibercept versus placebo in combination with fluorouracil, leucovorin and irinotecan in the treatment of previously treated metastatic colorectal cancer: prespecified subgroup analyses from the VELOUR trial. Eur J Cancer 2014;50:320331.

    • Search Google Scholar
    • Export Citation
  • 215.

    Folprecht G, Pericay C, Saunders MP. Oxaliplatin and 5-FU/folinic acid (modified FOLFOX6) with or without aflibercept in first-line treatment of patients with metastatic colorectal cancer: the AFFIRM study. Ann Oncol 2016;27:12731279.

    • Search Google Scholar
    • Export Citation
  • 216.

    CYRAMZA [package insert]. Indianapolis, IN: Eli Lilly and Company; 2015.

  • 217.

    Tabernero J, Yoshino T, Cohn AL. Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study. Lancet Oncol 2015;16:499508.

    • Search Google Scholar
    • Export Citation
  • 218.

    STIVARGA [package insert]. Whippany, NJ: Bayer HealthCare Pharmaceuticals Inc.; 2016.

  • 219.

    Li J, Qin S, Xu R. Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 2015;16:619629.

    • Search Google Scholar
    • Export Citation
  • 220.

    Belum VR, Wu S, Lacouture ME. Risk of hand-foot skin reaction with the novel multikinase inhibitor regorafenib: a meta-analysis. Invest New Drugs 2013;31:10781086.

    • Search Google Scholar
    • Export Citation
  • 221.

    Cutsem EV, Ciardiello F, Seitz JF. Results from the large, open-label phase 3b CONSIGN study of regorafenib in patients with previously treated metastatic colorectal cancer [abstract]. Ann Oncol 2015;26(Suppl 4):Abstract LBA-05.

    • Search Google Scholar
    • Export Citation
  • 222.

    Adenis A, de la Fouchardiere C, Paule B. Survival, safety, and prognostic factors for outcome with Regorafenib in patients with metastatic colorectal cancer refractory to standard therapies: results from a multicenter study (REBACCA) nested within a compassionate use program. BMC Cancer 2016;16:412.

    • Search Google Scholar
    • Export Citation
  • 223.

    Bendell JC, Rosen LS, Mayer RJ. Phase 1 study of oral TAS-102 in patients with refractory metastatic colorectal cancer. Cancer Chemother Pharmacol 2015;76:925932.

    • Search Google Scholar
    • Export Citation
  • 224.

    Yoshino T, Mizunuma N, Yamazaki K. TAS-102 monotherapy for pretreated metastatic colorectal cancer: a double-blind, randomised, placebo-controlled phase 2 trial. Lancet Oncol 2012;13:9931001.

    • Search Google Scholar
    • Export Citation
  • 225.

    LONSURF [package insert]. Tokyo, Japan: Taiho Pharmaceutical Co., Ltd.; 2015.

  • 226.

    Yoshino T, Uetake H, Fujita N. TAS-102 safety in metastatic colorectal cancer: results from the first postmarketing surveillance study. Clin Colorectal Cancer 2016;15:e205211.

    • Search Google Scholar
    • Export Citation
  • 227.

    Koopman M, Kortman GAM, Mekenkamp L. Deficient mismatch repair system in patients with sporadic advanced colorectal cancer. Br J Cancer 2009;100:266273.

    • Search Google Scholar
    • Export Citation
  • 228.

    Lochhead P, Kuchiba A, Imamura Y. Microsatellite instability and BRAF mutation testing in colorectal cancer prognostication. J Natl Cancer Inst 2013;105:11511156.

    • Search Google Scholar
    • Export Citation
  • 229.

    Venderbosch S, Nagtegaal ID, Maughan TS. Mismatch repair status and BRAF mutation status in metastatic colorectal cancer patients: a pooled analysis of the CAIRO, CAIRO2, COIN, and FOCUS studies. Clin Cancer Res 2014;20:53225330.

    • Search Google Scholar
    • Export Citation
  • 230.

    Topalian SL, Hodi FS, Brahmer JR. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012;366:24432454.

  • 231.

    KEYTRUDA [package insert]. Whitehouse Station, NJ: Merck & Co, Inc.; 2016.

  • 232.

    Le DT, Uram JN, Wang H. PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med 2015;372:25092520.

  • 233.

    OPDIVO [package insert]. Princeton, NJ: Bristol-Myers Squibb Company; 2015.

  • 234.

    Overman MJ, Kopetz S, McDermott RS. Nivolumab {+/–} ipilimumab in treatment (tx) of patients (pts) with metastatic colorectal cancer (mCRC) with and without high microsatellite instability (MSI-H): CheckMate-142 interim results [abstract]. J Clin Oncol 2016;34(Suppl):Abstract 3501.

    • Search Google Scholar
    • Export Citation
  • 235.

    Sul J, Blumenthal GM, Jiang X. FDA approval summary: pembrolizumab for the treatment of patients with metastatic non-small cell lung cancer whose tumors express programmed death-ligand 1. Oncologist 2016;21:643650.

    • Search Google Scholar
    • Export Citation
  • 236.

    Lewis C. Programmed death-1 inhibition in cancer with a focus on non-small cell lung cancer: rationale, nursing implications, and patient management strategies. Clin J Oncol Nurs 2016;20:319326.

    • Search Google Scholar
    • Export Citation
  • 237.

    Hofmann L, Forschner A, Loquai C. Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapy. Eur J Cancer 2016;60:190209.

    • Search Google Scholar
    • Export Citation
  • 238.

    Zimmer L, Goldinger SM, Hofmann L. Neurological, respiratory, musculoskeletal, cardiac and ocular side-effects of anti-PD-1 therapy. Eur J Cancer 2016;60:210225.

    • Search Google Scholar
    • Export Citation
  • 239.

    Naidoo J, Wang X, Woo KM. Pneumonitis in patients treated with anti-programmed death-1/programmed death ligand 1 therapy [published online ahead of print September 19, 2016]. J Clin Oncol, pii: JCO682005.

    • Search Google Scholar
    • Export Citation
  • 240.

    Nishino M, Chambers ES, Chong CR. Anti-PD-1 inhibitor-related pneumonitis in non-small cell lung cancer. Cancer Immunol Res 2016;4:289293.

  • 241.

    Nishino M, Sholl LM, Hodi FS. Anti-PD-1-related pneumonitis during cancer immunotherapy. N Engl J Med 2015;373:288290.

  • 242.

    Hecht JR, Cohn A, Dakhil S. SPIRITT: a randomized, multicenter, phase II study of panitumumab with FOLFIRI and bevacizumab with FOLFIRI as second-line rreatment in patients with unresectable wild type KRAS metastatic colorectal cancer. Clin Colorectal Cancer 2015;14:7280.

    • Search Google Scholar
    • Export Citation
All Time Past Year Past 30 Days
Abstract Views 1 0 0
Full Text Views 3938 2818 229
PDF Downloads 1135 852 109
EPUB Downloads 0 0 0